News Releases

scPharmaceuticals Inc. Presents Late-breaking FREEDOM-HF Study Data at the Heart Failure Society of America Annual Scientific Meeting 2021
Data show statistically significant and meaningful reduction in both heart failure-related and overall healthcare costs for patients treated with FUROSCIX® versus a historical comparator group Company on track to resubmit FUROSCIX NDA in the fourth quarter 2021 BURLINGTON, Mass. , Sept.[…]
scPharmaceuticals to Present at the Virtual H.C. Wainwright 23rd Annual Global Investment Conference
BURLINGTON, Mass. , Sept. 01, 2021 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today[…]
scPharmaceuticals Inc. Reports Second Quarter 2021 Financial Results and Provides Business Update
Received minutes from Type C meeting with the FDA confirming alignment on path toward resubmission of FUROSCIX ® NDA; no additional clinical data or device modifications required at this time; on track for resubmission in Q4 Announced positive top-line results from the FREEDOM-HF study[…]
scPharmaceuticals Inc. Announces Positive Top-Line Results from FREEDOM-HF Study
Reduced average 30-day heart failure related costs by $17,753 (p[…]
scPharmaceuticals Inc. Announces Receipt of Written Minutes from Type C Meeting with the FDA Regarding Development of FUROSCIX®
FDA and Company in alignment on the path forward No additional clinical data or device modifications required at this time FUROSCIX NDA resubmission targeted for Q4 2021 BURLINGTON, Mass. , July 01, 2021 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on[…]
scPharmaceuticals to Present at the Jefferies Virtual Healthcare Conference
BURLINGTON, Mass. , May 19, 2021 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today[…]
scPharmaceuticals Inc. Reports First Quarter 2021 Financial Results and Provides Business Update
FREEDOM clinical study on track for topline results in Q3 2021 Ended Q1 with cash, cash equivalents, restricted cash and investments of $96.5 million BURLINGTON, Mass. , May 12, 2021 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and[…]
scPharmaceuticals Inc. Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update
FUROSCIX® New Drug Application resubmission anticipated in Q3 2021 FREEDOM clinical study on track for topline results in Q3 2021 Ended Q4 with cash, cash equivalents, restricted cash and investments of $105.3 million , sufficient to fund operations through potential FUROSCIX approval and launch,[…]
scPharmaceuticals to Present in Two Upcoming Investor Conferences
BURLINGTON, Mass. , Feb. 25, 2021 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today[…]
scPharmaceuticals Inc. Announces Results of Type A End-of-Review Meeting with FDA Regarding FUROSCIX® NDA
No additional clinical efficacy, PK or safety data required December 31, 2020 cash, cash equivalents, restricted cash and investments estimated to be $105 million , sufficient to fund operations through potential FUROSCIX® approval and launch and into 2023 BURLINGTON, Mass. , Feb.[…]
scPharmaceuticals Inc. Appoints Renowned Heart Failure Specialist William T. Abraham, M.D., to its Board of Directors
BURLINGTON, Mass. , Feb. 17, 2021 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today[…]
scPharmaceuticals to Present at the 10th Annual SVB Leerink Global Healthcare Conference
BURLINGTON, Mass. , Feb. 11, 2021 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today[…]